This content is only available within our institutional offering.
14 Nov 2018
Rude Health - finnCap Life Sciences quarterly sector note
Allergy Therapeutics plc (AGY:LON), 19.7 | Avacta Group PLC (AVCT:LON), 123 | Bioventix Plc (BVXP:LON), 4,450 | Byotrol plc (BYOT:LON), 7.0 | Cambridge Cognition Holdings Plc (COG:LON), 73.5 | InnovaDerma PLC (IDP:LON), 49.0 | Inspiration Healthcare Group PLC (IHC:LON), 85.5 | Omega Diagnostics Group PLC (ODX:LON), 53.0 | OptiBiotix Health PLC (OPTI:LON), 55.5 | SDI Group plc (SDI:LON), 120 | Synairgen plc (SNG:LON), 156 | Tristel Plc (TSTL:LON), 580 | ANGLE plc (AGL:LON), 65.4 | Destiny Pharma Plc (DEST:LON), 113
-
-
-
Mark Brewer
-
32 pages
-


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Rude Health - finnCap Life Sciences quarterly sector note
Allergy Therapeutics plc (AGY:LON), 19.7 | Avacta Group PLC (AVCT:LON), 123 | Bioventix Plc (BVXP:LON), 4,450 | Byotrol plc (BYOT:LON), 7.0 | Cambridge Cognition Holdings Plc (COG:LON), 73.5 | InnovaDerma PLC (IDP:LON), 49.0 | Inspiration Healthcare Group PLC (IHC:LON), 85.5 | Omega Diagnostics Group PLC (ODX:LON), 53.0 | OptiBiotix Health PLC (OPTI:LON), 55.5 | SDI Group plc (SDI:LON), 120 | Synairgen plc (SNG:LON), 156 | Tristel Plc (TSTL:LON), 580 | ANGLE plc (AGL:LON), 65.4 | Destiny Pharma Plc (DEST:LON), 113
- Published:
14 Nov 2018 -
Author:
Mark Brewer -
Pages:
32 -
AIM Healthcare Index fell 10% in the past three months, compared with an 8.5% decline in the FT AIM All Share. The performance stats in the past month were more balanced, with AIM Health down 1.5% compared with a 3% decline in the AIM All Share. Despite this, ten finnLife 50 stocks showed positive gains with four rising by 15%+: namely Tiziana Life Sciences (+89% – FDA clearance to start Phase I trial with foralumab, an orally delivered antibody, and the announced intention to IPO on NASDAQ); Sinclair Pharma (+46% – agreed takeover); Omega Diagnostics (+28% – strategic update); and Creo Medical (+28% – product launch). Conversely, Diurnal shares fell c.80% on the back of a failed Phase III trial for Chronocort in chronic adrenal hyperplasia